Elicera Therapeutics AB (ELIC) — Cash Flow Quality Index

Latest as of September 2025: -15.58x

Elicera Therapeutics AB (ELIC) has a Cash Flow Quality Index of -15.58x as of September 2025. Operating cash flow of Skr-4.74 Million is below net income of Skr304.15K, suggesting accrual-heavy earnings not yet converted to cash. Also explore Elicera Therapeutics AB assets under control for the complete picture of this company's asset base.

Cash Flow Quality Index

-15.58x

Operating CF / Net Income

Operating Cash Flow

Skr-4.74 Million

SEK

Net Income

Skr304.15K

SEK

Data as of

Sep 2025

Most recent filing

Annual Cash Flow Quality Index for Elicera Therapeutics AB (None–None)

Year-by-year earnings quality comparison for Elicera Therapeutics AB. For live market cap and the full company financial profile, see ELIC market cap overview.

Year	Quality Index	Operating CF (SEK)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.